A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases

Inclusion Criteria: * Male or female ≥ 18 years of age and ≤ 60 years of age and a body mass index (BMI) \< 30 kg/m² or, in patients who have completed dosing with a vaccine against COVID-19 and are at least 1 month post the last dose, ≤ 65 years of age and BMI \< 35 kg/m\^2 * A diagnosis of one of a specified list of rheumatologic diseases at least 6 months prior to screening. * Stable dosing (or no use) of glucocorticoid or disease-modifying antirheumatic drugs (DMARDs) used for treatment of rheumatologic disease for ≥ 28 days prior to randomization. * Willing to practice study-required contraception. Exclusion Criteria: * Planning to change treatment for rheumatologic disorder within 4 months after randomization * Known immunodeficiency disorder or history of splenectomy, organ or cell-based transplantation, total lymphoid irradiation or T-cell vaccination or transfusion in prior 6 months * Treatment with prednisone or equivalent at a dose \> 10 mg/day or intraarticular, intravenous or intramuscular steroids within 28 days prior to screening * Treatment with any of the following medications within 28 days prior to screening (unless otherwise specified below) above the given doses: * Mycophenolate mofetil \> 2 g/day * Methotrexate \> 20 mg/week * Leflunomide \> 20 mg/day within 6 months prior to screening or receipt of leflunomide in combination with any dose of methotrexate * Azathioprine \> 2 mg/kg/day * Cyclosporine (except eye drops); tacrolimus (except topical), sirolimus, thalidomide, lenalidomide, 6-mercaptopurine, or voclosporin * Hydroxychloroquine \> 400 mg/day * Chloroquine \> 250 mg/day * Quinacrine \> 100 mg/day * Sulfasalazine \> 3 g/day, except that no more than 1 g/day is permitted if used in combination with methotrexate * Dapsone \> 100 mg/day * Danazol \> 800 mg/day * Any other nonbiologic immunosuppressive/immunomodulatory agent not already specified (eg, mizoribine, retinoids, adrenocorticotropic hormone analogs, dehydroepiandrosterone \[DHEA\]) within 2 weeks prior to screening. * Receipt of any biologic B cell-depleting therapy within 12 months or non-depleting B cell-directed therapy within 6 months * Receipt of abatacept, etanercept, or other biologic immunomodulatory agent or immunoglobulins within 3 months * Receipt of any other biologic disease modifying antirheumatic drug (bDMARD) not already specified, such as any targeted therapy (other than Janus kinase \[JAK\] inhibitor), or receipt of cyclophosphamide or chlorambucil within 6 months * Receipt of JAK inhibitors within 3 months * Receipt of anticoagulants other than anti-platelet drugs in prior 28 days * Active malignancy, history of malignancy within prior 10 years (limited exceptions) or known first degree relative with a hereditary cancer syndrome unless the patient is known to be free of the predisposing genetic mutation * Receipt of live vaccine or live therapeutic infectious agent within the 28 days prior to screening. * Pregnancy, lactation, or planning to become pregnant or donate/retrieve eggs before the end of study follow-up. * Hepatitis B or C infection, HIV infection, evidence of active TB or being at high risk for TB * History of any severe herpes virus infection (including any history of severe Epstein-Barr virus, cytomegalovirus disease, end-organ disease, disseminated herpes simplex, disseminated zoster, or ophthalmic zoster) or \> 1 episode of herpes zoster in the 2 years prior to screening and/or any opportunistic infection in the prior 2 years * Infection requiring parenteral antimicrobial therapy within 60 days of screening or any clinically significant active or suspected infection ( within 28 days prior to screening * History of anaphylaxis to any human immunoglobulin therapy or monoclonal antibody. * Blood tests at screening (performed in the central laboratory) that meet study requirements including but not limited to normal coagulation testing and glomerular filtration rate \< 50 mL/min/1.73 * High risk for COVID-19 or for severe COVID-19